Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
All the staff is super knowledgable and friendly
CJC-1295 with DAC has a longer half-life and is typically dosed once or twice weekly at higher amounts (1-2 mg)
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that remains unlicensed in the UK, with no MHRA approval, no NHS availability, and no BNF listing as of 20242025
Renal effects, including acute kidney injury, have been reported rarely in post-marketing surveillance, typically in the context of severe gastrointestinal adverse effects leading to dehydration
Proper storage extends the window where your products remain effective
PMID 13253565
US$ 25.07
US$ 22.24
US$ 24.97
